NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid ...

A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to ...

The patent on weight loss injection semaglutide is due to expire in 2031, which will let other companies make cut-price ...

Ireland has pivoted to oppose contentious European Union reforms aimed at broadening access to new drugs and medicines, ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...